Huntington’s disease (HD) is an incurable, fatal neurodegenerative disease that typically develops in the third to fifth decade of life. Although HD is rare, its pathology is strikingly similar to other more common neurodegenerative diseases including Parkinson’s and Alzheimer’s disease. No effective treatment exists currently for HD, but using a chemogenomic approach University of Pittsburgh researchers have demonstrated that synergy in neuroprotective drug activity can be a more effective therapy for HD than any single drug therapy in current clinical trials. This discovery has the potential to reduce symptom severity in HD patients and halt progression of the disease, effectively prolonging lifespan. It may also be applicable to the development of treatments for other incurable neurodegenerative disorders.